Tuberculosis: What's new in diagnos6cs and management?
|
|
- Leslie Johnston
- 6 years ago
- Views:
Transcription
1 Tuberculosis: What's new in diagnos6cs and management? Colin Menezes, Department of Internal Medicine, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand.
2 Objec6ves of this talk: Discuss what is new in the diagnos6cs of tuberculosis in South Africa. Discuss what is new in the management of drug sensi6ve and resistant tuberculosis. Discuss the management of TB in the selng of HIV co-infec6on drug interac6ons and side effects.
3 Epidemiology of tuberculosis The WHO es6mated 10.4 million new TB cases in 2015, and 580,000 people were es6mated to have had MDR-TB or RR-TB worldwide. An es6mated 9.7% of people with MDR-TB had XDR-TB. People living with HIV accounted for 1.2 million of all new cases. TB is s6ll one of the top 10 causes of death the number of TB deaths fell by 22% between 2000 and 2015 but there s6ll were 1.4 million deaths. South Africa is one of the countries with the highest burden of TB. It has an incidence of 454,000 cases of ac6ve TB with MDR-TB accoun6ng for about 3.3% of these new TB cases. WHO 2015; h`ps://
4 Tuberculosis in the cri6cally ill pa6ent Some of the reasons for ICU admission include organ failure - acute respiratory failure, liver failure and renal failure. Mortality for pa6ents admi`ed with ac6ve TB and respiratory failure requiring mechanical ven6la6on is poor, with in-hospital mortali6es of 33 to 67%. It is a treatable disease and a proac6ve approach is required. Delays to star6ng therapy can be associated with worse survival. TB pa6ents in ICU present special challenges - confirma6on of the diagnosis, providing effec6ve an6-tuberculosis treatment in the selng of poor absorp6on and organ dysfunc6on, is a challenge. Hagan G et al. Cri6cal Care 2013; 17:240
5 Diagnosis of TB In clinical prac6ce, the diagnosis can be difficult. Culture is the gold standard it has the highest sensi6vity for confirming ac6ve TB but take 4-6 weeks. Although microscopy is rapid and inexpensive, it has a low sensi6vity. Nucleic acid amplifica6on tests are highly sensi6ve for the rapid detec6on of MTB in a variety of specimens. South African Na/onal Tuberculosis Management Guidelines 2014
6 Xpert MTB/RIF Automated molecular plakorm to detect MTB complex and rifampicin resistance - targe6ng specific muta6ons in the rpob gene in sputum. Results available within 2 hours. It can also be used on CSF, aspirates and 6ssue. More sensi6ve test than smear microscopy, therefore it is possible to detect TB in smear nega6ve pa6ents in fact, case detec6on rates in HIV posi6ve pa6ents have increased by 45%. South African Na6onal Tuberculosis Management Guidelines Lawn et al, Clin Infect Dis 2012; 54:
7 Genotype MTBDRplus assay for first line drugs This a PCR based hybridisa6on assay. Can only be performed on smear or culture posi6ve sputum. Compared to phenotypic DST, results available within 48 hours. Simultaneously detects MTB complex, muta6ons in the rpob gene (rifampicin resistance) and muta6ons on the katg gene (higher levels of isoniazid resistance) and inha gene (lower levels of isoniazid resistance which is associated with ethionamide resistance). Cannot be used for monitoring pa6ents on treatment. South African Na6onal Tuberculosis Management Guidelines 2014
8 MDR with inha and katg muta6ons
9 What s new in TB diagnos6cs? MTBDRsl The availability of rapid second line drug tes6ng in MDR TB smear posi6ve and nega6ve pa6ents to exclude XDR TB. Allows for the rapid detec6on of fluoroquinolone and second line injectable resistance. It is now available with the introduc6on of the short MDR- TB treatment regimen. Cannot be used for monitoring pa6ents on treatment. Proposed South African draq 2017 guidelines courtesy of Dr Nazir Ismail, NICD
10 Evalua6on of the genotype MTBDRsl version 2.0 assay for second-line drug resistance detec6on of Mycobacterium tuberculosis isolates in South Africa Gardee Y, Dreyer AW, Koornhof HJ, Omar SV, da Silva P, Bhyat Z, Ismail NA Evalua6on of the genotype MTBDRsl version 2.0 assay for second-line drug resistance detec6on of Mycobacterium tuberculosis isolates in South Africa. J Clin Microbiol 55: FLQ SLID Published studies Sensitivity Specificity Sensitivity Specificity Tagliani et al (n=228) Gardee et al (n=268)
11 XDR TB
12 Anything new in the treatment of drug-suscep6ble tuberculosis? Current treatment includes a four drug regimen. This allows for a more than 95% cure rate. Use of rifampin with isoniazid allowed treatment to be shortened from 18 to 9 months, and the addi6on of pyrazinamide for the ini6al 2 months, allowed further shortening to 6 months. Trials conducted between 1948 and 1986 showed comple6on of 6 months therapy lead to a cure of drug sensi6ve tuberculosis. This is s6ll excep6onally long compared to dura6on of treatment of other bacterial infec6ons. It is associated with toxicity, affec6ng adherence which results in the interrup6on or discon6nua6on of treatment. By adding a fluoroquinolone, trials were undertaken to shorten treatment further to 4 months. Fox W et al. Int J Tuberc Lung Dis 1999; 3: S231-S279. Tuberculosis Trials Consor6um, Division of TB Elimina6on, CDC. Public Health Rep 2001; 116: Nunn AJ et al. Int J Tuberc Lung Dis 2010; 14:
13 Drug-suscep6ble TB disease: fluoroquinolone-containing regimens vs. the standard TB drug regimen. Unfortunately, higher relapse rates were noted at 18 months of follow-up, even though at 2 months a slightly higher (not sta6s6cally significant) rate of culture conversion was noted. No evidence of reduc6on of adverse events and no difference in all-cause and TB-related mortality was noted. As a result, there is a concern that this may lead to a rise in resistance and loss of fluoroquinolones for the treatment of drug-resistant TB. Therefore, fluoroquinolones not recommended for now. Gillespie SH et al. N Engl J Med. 2014;371(17): Merle CS et al. N Engl J Med. 2014;371(17): Jindani A et al. N Engl J Med. 2014;371(17): Jawahar MS et al. PLoS One. 2013;8(7):e WHO Guidelines for treatment of drugsuscep6ble tuberculosis and pa6ent care (2017 update)
14 Change in ART guidelines - ART interac6ons with rifampicin? Adult an6retroviral therapy guidelines S Afr J HIV Med. 2017;18(1), a776.
15 What s new in the treatment of drug resistant TB disease? Two new drugs are available for the treatment of drug resistant TB this includes bedaquiline and delamanid. The leprosy drug, clofazimine, repurposed for the treatment of MDR TB. In addi6on, with the availability of rapid second line resistance tes6ng one can opt for the short Bangladesh MDR TB regimen. Criteria for the short MDR TB regimen include confirmed rifampicin resistance or MDR TB with no resistance to second line injectables or fluoroquinolones. WHO Guidelines for treatment of drug-resistant tuberculosis and pa6ent care (2016 update)
16 Bedaquiline as a new drug for DR-TB It offers a new mechanism by specifically inhibi6ng mycobacterial adenosine triphosphate synthase enzyme. When given with other exis6ng MDR-TB drugs - increases the propor6on of sputum culture conversion to nega6ve aqer 2 and 6 months of treatment, essen6ally reducing the 6me to culture conversion and offering a shorter treatment dura6on. Approved by SA MCC for the na6onal TB program to treat XDR- TB or pre-xdr TB pa6ents in December 2012 via the Bedaquiline Clinical Access Programme (BCAP). Now registered in South Africa since October 2014 for use in HIV-nega6ve or HIVposi6ve, ART naïve pa6ents, 18 years or older and have laboratory confirmed MDR-TB. It is offered via the TB Directorate within the NDOH. South African draq 2017 guidelines courtesy of Dr Xavier Padinilam, Sizwe Hospital, Johannesburg.
17 Delamanid as a new drug for DR-TB A nitroimidazole with ac6vity against replica6ng bacilli through inhibi6on of mycolic acid synthesis and ac6ve against nonreplica6ng bacilli through genera6on of reac6ve nitrogen intermediates. When given with other exis6ng MDR-TB drugs - shown to improve sputum-culture conversion at 2 months. One must have the standard background therapy for MDR TB disease when using delamanid. Delamanid will be introduced in South Africa in a phased approach similar to bedaquiline via the Delamanid Clinical Access Programme. It is currently not registered in SA. South African draq 2017 guidelines courtesy of Dr Xavier Padinilam,, Sizwe Hospital, Johannesburg. Gler MT et al. N Engl J Med 2012; 366:
18 Clofazimine It is thought that it acts by inhibi6ng the forma6on of matrixes within the MTB DNA and thus delaying the growth of the bacterium. It was discovered in 1954 for TB treatment. At the 6me, the drug proved to be ineffec6ve at trea6ng TB but showed efficacy in trea6ng leprosy. A meta-analysis of studies show that it could have a major role in the treatment of MDR TB. The most effec6ve treatment regimen required to achieve a relapse-free cure of 87.9% includes a minimum of 9 months with clofazimine, ga6floxacin, ethambutol and pyrazinamide throughout the treatment period supplemented by prothionamide, kanamycin and high-dose isoniazid during an intensive phase of a minimum of 4 months. Dey T et al. J An6microb. Chemother : South African draq 2017 guidelines courtesy of Dr Xavier Padinilam, Sizwe Hospital, Johannesburg. h`p://
19 The short MDR TB treatment regimen Up to now, the total treatment dura6on recommended for MDR-TB pa6ents months. However the op6mal dura6on of treatment has been a ma`er of debate for years. Shorter regimens have recently been evaluated in Bangladesh and in other countries in Africa. The WHO guidelines have been updated in May 2016 in accordance with these findings, and have included a recommenda6on for the use of shorter treatment op6ons if criteria are met. WHO Guidelines for treatment of drug-resistant tuberculosis and pa6ent care (2016 update)
20 Treatment success rates: shorter MDR-TB regimen vs longer MDR-TB regimens WHO Guidelines for treatment of drug-resistant tuberculosis and pa6ent care (2016 update)
21 Short MDR TB regimen Bangladesh Regimen This includes a dura6on 9 to 12 months in adult, and paediatric popula6ons. Intensive phase: 4-6 months of Kanamycin, Moxifloxacin, Ethionamide, Clofazimine, Ethambutol, Pyrazinamide, INH (high dose). Con6nua6on phase: 5-6 months of Moxifloxacin, Clofazimine, Ethambutol, Pyrazinamide. Pregnant women offered the possibility of this short regimen with linezolid or bedaquiline or delamanid. Pa6ents need to be treated at a referral centre aqer approval has been received from the Na6onal Advisory Commi`ee. South African draq 2017 guidelines courtesy of Dr Xavier Padinilam. WHO Guidelines for treatment of drug-resistant tuberculosis and pa6ent care (2016 update)
22 Proposed algorithm Proposed South African draq 2017 guidelines courtesy of Dr Nazir Ismail, NICD
23 An6-TB drugs recommended for the treatment of rifampicin resistant and MDR TB update) WHO Guidelines for treatment of drug-resistant tuberculosis and pa6ent care (2016
24 Shared side effects of TB drugs and ART Meintjes G et al. Adult an6retroviral therapy guidelines S Afr J HIV Med. 2017;18(1), a776.
25 Conclusion South Africa is currently using all WHO endorsed DR-TB technologies and treatment therapies. All pa6ents should be tested for drug resistance as per diagnos6c algorithm. Early detec6on of SLT resistance is available since Jan 2017 but one must send off pdst. Need to monitor closely for drug side effects.
Shah: Discordant Growth- Molecular Rifampin Resistance 2/27/16 RELAPSED FAILED
/7/6 Discordant Growth- Molecular Diagnos7c Challenges and Treatment Outcomes Neha Shah, MD MPH Centers for Disease Control and Preven7on California Department of Health Tuberculosis Control NAR February
More informationEpidemiology and diagnosis of MDR-TB in children H Simon Schaaf
Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Definitions
More informationManagement of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore
Management of MDR TB Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Outline Global epidemiology of Tuberculosis Epidemiology of Tuberculosis
More informationThe shorter regimen for MDR-TB: evidence and pitfalls
The shorter regimen for MDR-TB: evidence and pitfalls Helen Cox 10 November 2017 What is the shortened regimen? Current conventional regimen (SA): Intensive Phase (at least 6 months): PZA / (EMB) / Kana
More informationHA Convention 2016 : Special Topic Session 3 May 2016
HA Convention 2016 : Special Topic Session 3 May 2016 Diagnosis and Management of TB in Adults Dr. Thomas Mok COS(RMD), KH Tuberculosis An airborne infectious disease caused by Mycobacterium tuberculosis
More informationMULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic
MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin
More informationElizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
More informationShort Course Treatment for MDR TB
Objectives Short Course Treatment for MDR TB Barbara J Seaworth M.D. Medical Director Heartland National TB Center Professor of Medicine, University of Texas Health Northeast Participants will utilize
More informationMSF Field Research. Diagnosis and management of drug-resistant tuberculosis. South African adults. Hughes, J; Osman, M
MSF Field Research Diagnosis and management of drug-resistant tuberculosis in South African adults Authors Citation DOI Publisher Journal Rights Hughes, J; Osman, M Diagnosis and management of drug-resistant
More informationMultiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health
Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health C. Robert Horsburgh, Jr. Boston University School of Public Health Background Outline Why does drug resistance threaten
More informationNew Drugs, New Treatments, Shorter Regimens
New Drugs, New Treatments, Shorter Regimens Sarah K. Brode, MD MPH FRCP(C) West Park Healthcare Centre, University Health Network, University of Toronto TB Elimination: Back to Basics November 16, 2016
More informationDrug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER
Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Outline Drug resistant TB: definitions and epidemiology How does TB become resistant? Current drug susceptibility
More informationKen Jost, BA, has the following disclosures to make:
Diagnosis of TB Disease: Laboratory Ken Jost, BA May 10, 2017 TB Intensive May 9-12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Ken Jost, BA, has the following disclosures to make: No conflict
More informationDiagnosis of drug resistant TB
Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million
More informationCLINICAL EXPERIENCE OF TREATING XDR- TB AT JOSE PEARSON TB HOSPITAL
CLINICAL EXPERIENCE OF TREATING XDR- TB AT JOSE PEARSON TB HOSPITAL BY DR LIMPHO RAMANGOAELA B.Sc.Ed(NUL),MBCHB(UKZN) 20 TH OCTOBER 2017 Livingstone Resource Centre. JOSE PEARSON TB HOSPITAL Out Line Overview
More informationOnline Annexes (5-8)
2016 Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs 1 Contents: Annex 5: GRADE summary of findings
More informationTB 101 Disease, Clinical Assessment and Lab Testing
TB 101 Disease, Clinical Assessment and Lab Testing Pacific Islands Tuberculosis Controllers Association Conference (PITCA) Clinical Laboratory Breakout None Disclosure Objectives Be able to list and explain
More informationOnline Annexes (5-8)
Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs THE END TB STRATEGY Online Annexes (5-8) to WHO
More informationManagement of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building
Management of Multidrug- Resistant TB in Children Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Objectives To review data on best practices for diagnosis, treatment and prevention
More informationTuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012
Tuberculosis New TB diagnostics. New drugs.new vaccines Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis (TB )is a bacterial disease caused by Mycobacterium tuberculosis (occasionally
More informationAssessing the programmatic management of drug-resistant TB
Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many
More informationTB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai
TB/HIV 2 sides of the same coin Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai Global- Tb new cases Diagnosis-Microscopy ZN,Flourescent microscopy(fm) Rapid, inexpensive test Specificity>95%
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationGlobal epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos
Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe
More informationWhat is the recommended shorter treatment regimen for MDR-TB?
DRTB STAT + TAG BRIEF Is shorter better? Is shorter better? Understanding the shorter regimen for treating drugresistant tuberculosis by Safiqa Khimani Edited by Vivian Cox, Mike Frick, Jennifer Furin,
More informationMycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline
Mycobacteria Diagnostic Testing in Manitoba Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline Acknowlegements: Assunta Rendina: Charge Tech HSC Lab Joyce Wolf & Dr. Meenu Sharma: NML Dr. Kanchana
More informationFIND and NDWG symposium Panel Discussion. Martina Casenghi, NDWG Core Group
FIND and NDWG symposium Panel Discussion Martina Casenghi, NDWG Core Group 48 Union World Conference, Guadalajara October 11th 2017 Molecular tests for diagnosis of TB and drug resistance 2008 Dec 2010
More informationGLI model TB diagnostic algorithms
GLI model TB diagnostic algorithms GLI model TB diagnostic algorithms Revised June 2018 Contents Acknowledgements Abbreviations v vi Background 1 Algorithm 1: Preferred algorithm for universal patient
More informationPhase III Clinical Trial Results at the 48 th Union World Conference on Lung Health: Implications for the Field 1
Phase III Clinical Trial Results at the 48 th Union World Conference on Lung Health: Implications for the Field 1 Preliminary results from two phase III drug-resistant TB (DR-TB) clinical trials were presented
More informationOverview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing
Overview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing 1. Essentials for the Mycobacteriology Laboratory: Promoting Quality Practices 1.1 Overview: Mycobacterial Culture, Identification,
More informationMDR-TB ELIMINATION: WHAT WILL IT COST?
MDR-TB ELIMINATION: WHAT WILL IT COST? Emily A. Kendall, MD Assistant Professor, Infectious Diseases, Johns Hopkins University School of Medicine 48 th Union World Conference on Lung Health, Guadalajara,
More informationStacy White, PhD May 12, TB for Community Providers. Phoenix, Arizona
Role of the Laboratory in TB Diagnosis Stacy White, PhD May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION Stacy White, PhD has the following disclosures
More informationGLI model TB diagnostic algorithms
GLI model TB diagnostic algorithms GLI model TB diagnostic algorithms March 2017 Contents Acknowledgements Abbreviations v vi Background 1 Algorithm 1: Preferred algorithm for universal patient access
More informationHIV Clinicians Society Conference TB/HIV Treatment Cascade
HIV Clinicians Society Conference-2012 TB/HIV Treatment Cascade Dr Judith Mwansa-Kambafwile Wits Reproductive Health & HIV Institute University of Witwatersrand TB/HIV Treatment Cascade Overview TB stats
More informationSoedarsono Department of Pulmonology & Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital
Soedarsono Department of Pulmonology & Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital There were an estimated 10.4 million new TB cases in 2015, higher than
More informationNew TB Medications. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention New TB Medications Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers
More informationUpcoming TB Alliance Studies. CPRT DST Review September, 2014
Upcoming TB Alliance Studies CPRT DST Review September, 2014 STAND PaMZ Ph 3 STAND: Phase 3 Trial of the Pa-M-Z Regimen Participants with newly diagnosed smear positive DS- and MDR-TB DS Pa(100mg)-M-Z
More informationWhole Genome Next Genera/on Sequencing of TB in a Public Health Laboratory: A New Diagnos/c Era
Whole Genome Next Genera/on Sequencing of TB in a Public Health Laboratory: A New Diagnos/c Era March 31, 2016 Kimberlee Musser, PhD Chief, Bacterial Diseases Wadsworth Center 900,000 sq. O. state- of-
More informationWELCOME. Lab Talk: What a Nurse Hears. April 18, NTNC Annual Meeting Lab Talk: What a Nurse Hears
Lab Talk: What a Lab Talk: What a Max Salfinger, MD, FIDSA, FAAM Executive Director, Advanced Diagnostic Laboratories Laboratory Director, Mycobacteriology & Pharmacokinetics National Jewish Health Lisa
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationOptimising patient care in MDR TB with existing molecular screening tests in high burden countries
Optimising patient care in MDR TB with existing molecular screening tests in high burden countries Camilla Rodrigues MD Consultant Microbiologist Hinduja Hospital,India Outline What is the best empiric
More informationMolecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis.
Title Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium. Author(s) Ho, PL; Yam, WC; Leung, CC; Yew, WW; Mok, TYW; Chan, KS; Tam, CM Citation Hong Kong Medical
More informationPyrosequencing Experience from Mumbai, India. Camilla Rodrigues MD Consultant Microbiologist Hinduja Hospital,Mumbai India
Pyrosequencing Experience from Mumbai, India Camilla Rodrigues MD Consultant Microbiologist Hinduja Hospital,Mumbai India Mumbai maximum city Slow Fast 1-2 D With increasing drug resistance, DST is vital
More informationHot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs
Slide 1 Hot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs Constance A. Benson, M.D. Professor of Medicine Division of Infectious Diseases University of California, San Diego
More informationSirturo: a new treatment against multidrug resistant tuberculosis
Sirturo: a new treatment against multidrug resistant tuberculosis TB is an on-going problem WHO estimated incidence of new TB cases 2009 Global Tuberculosis Control: WHO report 2010. Available at: http://www.who.int/tb/publications/global_report/2010/en/index.html
More informationDisclosure Informa0on Western Occupa0onal Health Conference 2012
Infec&ous Disease: Guidelines, Updates & Implementa&on in the Health Care Se=ng James Watt, MD, MPH Chief, Division of Communicable Disease Control Center for Infectious Diseases California Department
More informationInformation Note. WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis
Information Note WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis In order to ensure that the upcoming comprehensive revision of WHO policies on treatment
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationCurrent Status in the Development of the New Anti-Tuberculosis Drugs
National Scientific Meeting TB UPDATE IX 2017 WORKSHOP AND SYMPOSIUM Novel Management to End TB Hotel Bumi Surabaya 29-30 April 2017 Current Status in the Development of the New Anti-Tuberculosis Drugs
More informationPatients at High Risk Experience, Guidelines, and Best Practices. Mozambique. José Tique, MD MPH MoH July 17-19, 2017 Harare, Zimbabwe
Patients at High Risk Experience, Guidelines, and Best Practices Mozambique José Tique, MD MPH MoH July 17-19, 2017 Harare, Zimbabwe Content Scope of the Problem Treatment Guidelines Best Prac9ces Differen9a9ng
More informationMolecular assays in Tuberculosis. Jatin Yegurla Junior resident
Molecular assays in Tuberculosis Jatin Yegurla Junior resident 17-3-2018 Contents Introduction TB-PCR Line Probe assay (LPA) GenoType MTBDRsl test (Second line LPA) Xpert MTB/RIF (GeneXpert) (CB-NAAT)
More informationIMPAACT TB SCIENTIFIC COMMITTEE. Anneke C Hesseling: Chair Sharon Nachman: Interim Vice Chair IMPAACT Vice Chair
IMPAACT TB SCIENTIFIC COMMITTEE Anneke C Hesseling: Chair Sharon Nachman: Interim Vice Chair IMPAACT Vice Chair Goal Address cri>cal therapeu>c research gaps in the preven>on and treatment of tuberculosis
More informationDRUG RESISTANCE IN TUBERCULOSIS
DRUG RESISTANCE IN TUBERCULOSIS INTRODUCTION Up to 50 million people may be infected with drug-resistant resistant TB.* Hot zones of MDR-TB such as Russia, Latvia, Estonia, Argentina and the Dominican
More informationClinical Infectious Diseases MAJOR ARTICLE
Clinical Infectious Diseases MAJOR ARTICLE Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin- Resistant Tuberculosis on Xpert MTB/RIF: A Multisite
More informationThe Evaluation of Effectiveness and Safety of Novel Shorter. Treatment Regimens for Multidrug-Resistant Tuberculosis
The Evaluation of Effectiveness and Safety of Novel Shorter Treatment Regimens for Multidrug-Resistant Tuberculosis Operational Research Protocol Template May 2018 A publication of the Global Drug-resistant
More informationNewer anti-tb drugs and regimens. DM Seminar
Newer anti-tb drugs and regimens DM Seminar 31-10-14 Why are newer drugs/regimens needed? Problems with current drugs/regimens Drug resistance Drug interaction of anti-tubercular drugs with ART Long duration
More informationDefinitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013
Definitions and reporting framework for tuberculosis 2013 revision Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013 2-year revision process WHO/HTM/TB/2013.2 2 www.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
More informationMaha R Farhat, MD MSc Massachusetts General Hospital Harvard Medical School. I have no financial or other potential conflicts of interest to disclose
Maha R Farhat, MD MSc Massachusetts General Hospital Harvard Medical School I have no financial or other potential conflicts of interest to disclose Update on the epidemiology of TB drug resistance Success
More informationKritische Fragen zum Beitrag der kombinierten PCR für den Nachweis von M. tuberculosis und der Identifizierung von Mutationen auf dem rpob-gen
Kritische Fragen zum Beitrag der kombinierten PCR für den Nachweis von M. tuberculosis und der Identifizierung von Mutationen auf dem rpob-gen Hans L Rieder Union Internationale Contre la Tuberculose et
More informationRevised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor
Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor Global scenario*: Burden of TB Incidence : 9.6 million (58% SEAR and Western Pacific) Deaths : 1.5 million
More informationAntimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018
Antimycobacterial drugs Dr.Naza M.Ali lec 14-15 6 Dec 2018 About one-third of the world s population is infected with M. tuberculosis With 30 million people having active disease. Worldwide, 9 million
More informationCertainty assessment of patients Effect Certainty Importance. a standardised 9 month shorter MDR-TB regimen. e f
Author(s): STREAM Stage 1 Trial investigators reported for the Guideline Development Group for the WHO treatment guidelines on MDR/RR-TB, 2018 update (6 July 2018) - FINAL RESULTS Question: PICO 1. In
More information- UPDATE - Implementation and roll-out of Xpert MTB/RIF October 2011
- UPDATE - Implementation and roll-out of Xpert MTB/RIF October 2011 This document provides an update on the global roll-out of Xpert MTB/RIF, the WHO-endorsed test for the rapid and simultaneous detection
More informationNEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY
NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY Neil W. Schluger, M.D. Professor of Medicine, Epidemiology and Environmental Health Sciences Columbia University Global tuberculosis incidence
More informationManaging Complex TB Cases Diana M. Nilsen, MD, RN
Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private
More informationIntroduction. Diagnosis of extrapulmonaryand paediatric tuberculosis. Extrapulmonary tuberculosis EPTB SASCM WORKSHOP 2014/05/24
Diagnosis of extrapulmonaryand paediatric tuberculosis AW Dreyer Centre for Tuberculosis NICD Introduction Part of the global efforts to control tuberculosis (TB) include improving case detection, especially
More informationEpidemiology of drug-resistant tuberculosis among children and adolescents in South Africa
Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa 2005 2010 BK Moore 1, E Anyalechi 1, M van der Walt 2, S Smith 1, L Erasmus 3, J Lancaster 2, S Morris 1, N Ndjeka
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Diagnosis of TB: Laboratory Ken Jost, BA November 12, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant
More informationDST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps?
DST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps? Mark Nicol Division of Medical Microbiology and Institute for Infectious Diseases and
More informationGenotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens
EDITORIAL TUBERCULOSIS Genotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens Andrea Maurizio Cabibbe Giovanni Battista Migliori 1, Giovanni Sotgiu 2,
More informationRapid Diagnosis and Detection of Drug Resistance in Tuberculosis
Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis YAM Wing-Cheong 任永昌 Department of Microbiology The University of Hong Kong Tuberculosis Re-emerging problem in industrialized countries
More informationSoedarsono Department of Pulmonology and Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital
Soedarsono Department of Pulmonology and Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital MDR-TB is a public health crisis 480 000 people developed MDR-TB in
More informationUpdate on Management of
Update on Management of DR TB Definitions Presumptive MDR-TB A patient suspected of drug-resistant TB, based on RNTCP criteria for submission of specimens for drug-susceptibility testing MDR-TB Case A
More informationPrinciples and practice of treating drug-sensitive TB
Principles and practice of treating drug-sensitive TB Brian Eley Paediatric Infectious Diseases Unit Red Cross War Memorial Children s Hospital Department of Paediatrics and Child Health University of
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Günther G, Lange C, Alexandru S, et al. Treatment outcomes
More informationTuberculosis: Iden0fica0on and Suscep0bility Tes0ng. Andrew Hansen, MD Pathology Seminar Series 7/23/2012
Tuberculosis: Iden0fica0on and Suscep0bility Tes0ng Andrew Hansen, MD Pathology Seminar Series 7/23/2012 James (Jim) Bowie April 10, 1796 March 6, 1836 Outline TB review Iden0fica0on Smears Cultures Molecular
More informationCDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service
CDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service Beverly Metchock, DrPH, D(ABMM) Team Lead, Reference Laboratory
More informationDevelopment of New Regimens for Tuberculosis Zhenkun Ma, Ph.D.
Development of New Regimens for Tuberculosis Chief Scientific Officer Global Alliance for TB Drug Development 40 Wall Street, 24th Floor New York, NY 10005 USA 1 Outline What are the unmet needs in TB
More informationMultidrug-resistant tuberculosis in children
Multidrug-resistant tuberculosis in children James Seddon Clinical Lecturer Imperial College London UCL-TB and LSHTM TB Centre World TB Day 2015 24th March 2015 Outline Burden Recent studies Preventive
More informationWSLH Testing and Surveillance Updates
WSLH Testing and Surveillance Updates Wisconsin Mycobacteriology Laboratory Network annual conference November 4, 2015, Madison, WI Updates Outline Collection and Transport Smear and Culture Nucleic Acid
More informationPharmacokinetics and doses of antituberculosis drugs in children
Pharmacokinetics and doses of antituberculosis drugs in children HS Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health Stellenbosch University Declarations I have no conflict of interest
More informationFrances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS
The Laboratory s Role in Caring for Patients Diagnosed with TB Frances Morgan, PhD October 21, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE
More informationImplementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB. Global Consultation
Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB Global Consultation Geneva, 30 November 2010 Mario C. Raviglione, M.D. Director, Stop TB Department WHO, Geneva,
More informationThe Lancet Infectious Diseases
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study Susan E Dorman, Samuel G Schumacher, David Alland et al. 2017
More informationWHO posi)on paper on influenza vaccines*
WHO posi)on paper on influenza vaccines* Geneva, Switzerland Published in the Weekly Epidemiological Record on 23 November 2012 * This posi(on paper is concerned mainly with vaccines and vaccina(on against
More informationNew Standards for an Old Disease:
New Standards for an Old Disease: Practical Implications of the TB Standards TB Prevention and Control Saskatchewan September 16, 2015 Practical Implications of the TB Standards Learning Objectives At
More informationTherapeutic TB vaccines Shortening Treatment for (DS- and) DR-TB?
Therapeutic TB vaccines Shortening Treatment for (DS- and) DR-TB? Mark Hatherill South African Tuberculosis Vaccine Initiative (SATVI) University of Cape Town, South Africa 1 1. The need for a therapeutic
More informationNew Frontiers: Innovation and Access
8 th Regional TB Symposium - Tashkent, Uzbekistan New Frontiers: Innovation and Access New Guidelines: An Opportunity for National Programmes and Patients: Evidence for new WHO recommendations on MDR-TB
More informationAPSR RESPIRATORY UPDATES
Volume 11 Issue 1 Newsletter Date: January 2019 APSR EDUCATION PUBLICATION Inside this issue: Updates on Treatment in Drug Resistant Tuberculosis World TB Day 2018: the challenge of drug resistant tuberculosis
More informationCompassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India
AGORA RESEARCH LETTER Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India To the Editor: Bedaquiline, a mycobacterial ATP synthase inhibitor [1], is the first
More informationThe treatment of patients with initial isoniazid resistance
The treatment of patients with initial isoniazid resistance 2011 INTERTB Meeting, St George s, London Patrick Phillips, MRC Clinical Trials Unit DA Mitchison, AJ Nunn. 21 st October 2011 Outline Background
More informationMultidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment
Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment L. P. Ormerod Chest Clinic, Blackburn Royal Infirmary, Blackburn, Lancs BB2 3LR, and Postgraduate School of Medicine and
More information4-6 Km-Mfx-Pto-Cfz-Z-H high-dose -E / 5 Mfx-Cfz-Z-E
Frequently asked questions about the implementation of the new WHO recommendation on the use of the shorter MDR-TB regimen under programmatic conditions Version: 20 December 2016 These FAQs are to be read
More informationOutbreak response in post- OPV2 withdrawal era. Strategic Advisory Group of Experts (SAGE) on immuniza;on, Geneva, 22 October 2014
Outbreak response in post- OPV2 withdrawal era Strategic Advisory Group of Experts (SAGE) on immuniza;on, Geneva, 22 October 2014 Request to SAGE Endorse the principles for outbreak response in post- OPV2
More informationAuthor s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis
Author s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis Authors: Phan Thai (phanvuongkhacthai@yahoo.com) Dang Ha
More informationLaboratory Diagnosis for MDR TB
Laboratory Diagnosis for MDR TB Neha Shah MD MPH Centers for Disease Control and Prevention Division of Tuberculosis Elimination California Department of Public Health Guam March 07 Objectives Describe
More informationManagement of Drug-resistant Tuberculosis (DR-TB)
Management of Drug-resistant Tuberculosis (DR-TB) Nitipatana Chierakul Division of Respiratory Disease & Tuberculosis Department of Medicine Faculty of Medicine Siriraj Hospital October 14 th, 2008 Tropical
More informationThe clinical pharmacology and drug interactions of bedaquiline
7 TH FIDSSA 2017 The clinical pharmacology and drug interactions of bedaquiline Helen McIlleron Division of Clinical Pharmacology University of Cape Town 20 years 2 drugs conditional approval based on
More informationTOG The Way Forward
TOG 2016- The Way Forward Main Changes in Diagnostic algorithm Definition (Type, Classification, Outcome) Registration at the time of Diagnosis (PHI level Notification Register) Long term follow up (till
More informationStudy of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan
Journal of Basic & Applied Sciences, 2018, 14, 107-112 107 Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan Sana Saeed 1, Moosa Raza
More information